rosiglitazone has been researched along with Encapsulating Peritoneal Sclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, J; Gao, X; Li, J; Li, W; Li, Z; Lu, M; Meng, P; Zhang, Y | 1 |
1 other study(ies) available for rosiglitazone and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
PPARĪ³ alleviates peritoneal fibrosis progression along with promoting GLUT1 expression and suppressing peritoneal mesothelial cell proliferation.
Topics: Animals; Cell Proliferation; Creatinine; Dialysis Solutions; Glucose; Glucose Transporter Type 1; Nitrogen; Peritoneal Fibrosis; PPAR gamma; Prostaglandin D2; Rats; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta; Urea | 2022 |